Kidney Disease
Recently Published Documents


(FIVE YEARS 30489)



2021 ◽  
Vol 78 (6) ◽  
pp. 564-570
Hsin-Fu Lee ◽  
Yu-Wen Cheng ◽  
Jian-Rong Peng ◽  
Chiu-Yi Hsu ◽  
Chia-Hung Yang ◽  

2021 ◽  
Vol 45 ◽  
pp. 100580
Hui-Yeon Ko ◽  
Joonyoung Kim ◽  
Migyeong Geum ◽  
Ha-Jung Kim

Circulation ◽  
2021 ◽  
Vol 144 (Suppl_1) ◽  
Ernesto A Ruiz ◽  
Aaqib Malik ◽  
Kampaktsis Polydoros ◽  
Alexandros Briasoulis

Introduction: Pulmonary artery pressure (PAP)-guided therapy in patients with heart failure (HF) using the CardioMEMS device (CMM), an implantable PAP sensor, has shown to reduce hospitalizations in prior studies. Hypothesis: We sought to evaluate the clinical benefit of the CMM device in regard to readmission rates using the National Readmission Database (NRD). Methods: We queried the NRD to identify patients who underwent CMM implantation (CPT code 33289) between years 2014 to 2018 and studied their HF readmissions. We compared CMM patients and their readmissions with a matched cohort of patients with HF without CMM. Multivariate Cox regression analysis was performed to adjust for other predictors of readmissions. Results: Prior to matching we identified 3,965,188 weighted HF patients without CMM and 1528 patients with CMM. After propensity score matching for several patient and hospital related characteristics, the cohort consisted of 1528 patients with CMM and 1528 with HF without CMM. Before matching CMM patients were younger, more frequently males, with higher rates of prior myocardial infarction and chronic kidney disease. Readmission rates at 30-days were 17.6% vs. 21% for patients with vs. without CMM respectively and remained statistically significant after matching (17.5% vs. 22.7%, p=0.01). The rates of 90-day (29.1% vs 36.5%, p=0.002) and 180-day (40.1% vs. 46.6%, p=0.03) readmissions were lower in the CMM group (Figure). In multivariable regression models, CMM was associated with lower risk of readmissions (HR, 0.78, 95% CI 0.64-0.94, p=0.01). Conclusions: The CardioMEMS device was associated with reduced HF rehospitalization rates in a nationally representative cohort of HF patients

Hypertension ◽  
2021 ◽  
Vol 78 (5) ◽  
pp. 1365-1367
Vincent D. Salvador ◽  
George L. Bakris

Cureus ◽  
2021 ◽  
Asfia Jabbar ◽  
Ruqaya Qureshi ◽  
Murtaza Dhrolia ◽  
Kiran Nasir ◽  
Aasim Ahmad

2021 ◽  
pp. 20-25
N. V. Teplova ◽  
G. A. Chervyakova ◽  
A. G. Vardanyan ◽  
S. E. Arakelov ◽  
A. G. Dzheksembekov ◽  

Hypertensive disorders in pregnant women are a significant factor in the development of complications leading to maternal and perinatal mortality. However, most cases of adverse outcomes are preventable. The choice of drug therapy in this group of patients should be made on the basis of a complete analysis and risk stratification.Purpose of work. Consideration of modern classification, diagnostic methods and rational antihypertensive therapy of chronic arterial hypertension on the example of a clinical case of a pregnant patient in a therapeutic hospital.Case description. The presented work describes a case of severe arterial hypertension during the first trimester of pregnancy, poorly amenable to drug correction.Conclusion. The features of this clinical observation are the problems associated with the selection of antihypertensive therapy for severe arterial hypertension during low gestational age pregnancy, taking into account comorbidities

2021 ◽  
Vol 30 (4) ◽  
pp. 294-299
Maria Mattera ◽  
Nicola Veronese ◽  
Filippo Aucella ◽  
Luciana La Tegola ◽  

2021 ◽  
Vol 12 (10) ◽  
pp. 1765-1777
Marek Saracyn ◽  
Bartłomiej Kisiel ◽  
Maria Franaszczyk ◽  
Dorota Brodowska-Kania ◽  
Wawrzyniec Żmudzki ◽  

Jenny Weinbrand-Goichberg ◽  
Efrat Ben Shalom ◽  
Choni Rinat ◽  
Sapir Choshen ◽  
Shimrit Tzvi-Behr ◽  

2021 ◽  
Vol 60 (20) ◽  
pp. 3261-3265
Tatsuya Suwabe ◽  
Masahiko Oguro ◽  
Yoshifumi Ubara ◽  
Daisuke Ikuma ◽  
Hiroki Mizuno ◽  

Sign in / Sign up

Export Citation Format

Share Document